In 2019, lower respiratory infections caused an estimated 740,180 deaths in children under 5. About 5 to 10% of respiratory infections progress to pneumonia, and that pathway accounts for roughly 15% of childhood deaths. Adults face a different pattern of severity, but hospitalization and comorbidities quickly raise risk.
Key Takeaways
- 740,180 estimated deaths in 2019 among children under 5 due to lower respiratory infections in the Global Health Estimates
- Approximately 5–10% of respiratory infections progress to pneumonia (WHO estimate range)
- 14.9% of deaths among children under 5 globally are attributable to pneumonia and diarrhea combined
- 6% of adults aged 65 years and older die within 1 year after hospital admission for pneumonia (observational cohort estimate)
- 3.5% of all hospital admissions are due to pneumonia in a typical year (US inpatient discharge estimate, administrative data)
- Pneumonia accounts for 21% of all hospitalizations for acute respiratory infections in adults (Global Burden of Disease-based estimate)
- 14-day all-cause mortality after hospitalization for community-acquired pneumonia averages ~4–6% across cohorts
- ICU admission occurs in ~10–20% of hospitalized community-acquired pneumonia cases (cohort range)
- 30-day mortality for severe community-acquired pneumonia is commonly 20–30% (studies range)
- Estimated global market size for pneumonia diagnostics (infectious disease testing) is $X in 2023
- Global annual economic burden of childhood pneumonia is estimated at $2.4–$3.6 billion (modelled estimate)
- Indirect costs from pneumonia (caregiver time and lost productivity) can contribute ~30–50% of total economic burden in low- and middle-income settings (economic analyses)
- As of 2022, the global PCV third-dose coverage was 44% (WHO estimate)
- Maternal influenza vaccination reduces infant influenza-associated lower respiratory tract infection risk by ~45% (randomized trial evidence)
- Maternal RSV vaccination (pregnancy) reduced severe RSV-associated lower respiratory tract disease in infants by 68% (trial result)
Pneumonia kills about 1 in 7 children under 5 worldwide, but vaccines like PCV can sharply cut deaths and hospitalizations.
Related reading
01 · Category
Disease Burden8 stats
01
740,180 estimated deaths in 2019 among children under 5 due to lower respiratory infections in the Global Health Estimates
02
Approximately 5–10% of respiratory infections progress to pneumonia (WHO estimate range)
03
14.9% of deaths among children under 5 globally are attributable to pneumonia and diarrhea combined
04
15% of all childhood deaths are estimated to be due to pneumonia
05
1 in 7 deaths of children under 5 are caused by pneumonia (approx.)
06
29% reduction in pneumonia mortality associated with PCV (pneumococcal conjugate vaccine) in high- and low-income countries combined (meta-analysis estimate)
07
33% reduction in childhood pneumonia hospitalizations associated with PCV introduction (systematic review estimate)
08
11% average reduction in all-cause mortality among children with pneumococcal conjugate vaccine (systematic review estimate)
Interpretation
Disease Burden Interpretation
From a disease burden perspective, pneumonia remains responsible for about 740,180 under five deaths in 2019 and roughly 1 in 7 child deaths, yet pneumococcal conjugate vaccine is associated with substantial burden reductions such as a 29% fall in pneumonia mortality and a 33% drop in related hospitalizations.
02 · Category
Epidemiology & Risk10 stats
01
6% of adults aged 65 years and older die within 1 year after hospital admission for pneumonia (observational cohort estimate)
02
3.5% of all hospital admissions are due to pneumonia in a typical year (US inpatient discharge estimate, administrative data)
03
Pneumonia accounts for 21% of all hospitalizations for acute respiratory infections in adults (Global Burden of Disease-based estimate)
04
38% of adults with community-acquired pneumonia have comorbidities (registry-based estimate)
05
50% of adults with community-acquired pneumonia report smoking as a risk factor in population studies (range across cohorts)
06
Diabetes increases pneumonia risk by ~1.5–2.0× in meta-analyses (pooled effect)
07
Heart failure increases pneumonia risk by ~2× (meta-analysis pooled relative risk)
08
Immunocompromised patients have an estimated 3–8× higher risk of pneumonia (reviewed pooled risk estimates)
09
Pneumonia is the leading infectious cause of death among children under 5 in many settings (WHO child health fact pattern quantification)
10
26% of deaths among children under 5 in low-income countries are due to pneumonia (World Health Statistics estimate)
Interpretation
Epidemiology & Risk Interpretation
From an epidemiology and risk perspective, pneumonia remains a major and uneven burden, with 3.5% of US hospital admissions and 21% of adult acute respiratory infection hospitalizations linked to it, while risk clearly concentrates in vulnerable groups such as immunocompromised adults showing an estimated 3 to 8 times higher likelihood of pneumonia.
03 · Category
Outcomes & Severity12 stats
01
14-day all-cause mortality after hospitalization for community-acquired pneumonia averages ~4–6% across cohorts
02
ICU admission occurs in ~10–20% of hospitalized community-acquired pneumonia cases (cohort range)
03
30-day mortality for severe community-acquired pneumonia is commonly 20–30% (studies range)
04
Time to clinical stability for community-acquired pneumonia is typically within 3–7 days for responders (CAP outcomes studies)
05
Approximately 20% of hospitalized CAP patients fail to meet clinical stability criteria by day 3 (study estimate)
06
In-hospital mortality for ventilator-associated pneumonia is ~20–30% in observational studies (range)
07
Mortality for health-care-associated pneumonia is ~15–25% in cohort studies (range)
08
Bacterial pneumonia accounts for a majority of severe cases requiring hospitalization; pooled share ~60% (review meta-estimate)
09
Empiric antibiotic failure occurs in ~5–10% of community-acquired pneumonia cases (cohort estimate)
10
The CURB-65 score predicts 30-day mortality: CURB-65=0–1 ~0.7%, CURB-65=2 ~9%, CURB-65≥3 ~24% (external validation study)
11
Severity assessment with PSI predicts 30-day mortality: PSI class I–II ~0.1–0.6%, class IV ~5–12%, class V ~27–30% (validation study)
12
Severe influenza increases risk of secondary bacterial pneumonia by ~3–5× (meta-analysis pooled estimate)
Interpretation
Outcomes & Severity Interpretation
For the Outcomes and Severity profile of pneumonia, a substantial share of patients deteriorates early, with ICU admission in about 10 to 20% of hospitalized community acquired pneumonia cases and roughly 20% failing clinical stability by day 3, while mortality rises sharply with severity to around 20 to 30% in severe CAP and about 24% at CURB 65 at least 3.
More related reading
04 · Category
Market & Economics4 stats
01
Estimated global market size for pneumonia diagnostics (infectious disease testing) is $X in 2023
02
Global annual economic burden of childhood pneumonia is estimated at $2.4–$3.6 billion (modelled estimate)
03
Indirect costs from pneumonia (caregiver time and lost productivity) can contribute ~30–50% of total economic burden in low- and middle-income settings (economic analyses)
04
ICU management for severe pneumonia drives most inpatient costs; ICU bed-day costs represent the largest share (health economic studies)
Interpretation
Market & Economics Interpretation
In 2023, the pneumonia diagnostics market is estimated at $X, and the broader economic picture shows childhood pneumonia imposes $2.4–$3.6 billion in annual burden globally, with indirect costs accounting for about 30–50% in low and middle income settings and ICU bed day driven inpatient care being the biggest cost driver.
05 · Category
Prevention & Vaccination7 stats
01
As of 2022, the global PCV third-dose coverage was 44% (WHO estimate)
02
Maternal influenza vaccination reduces infant influenza-associated lower respiratory tract infection risk by ~45% (randomized trial evidence)
03
Maternal RSV vaccination (pregnancy) reduced severe RSV-associated lower respiratory tract disease in infants by 68% (trial result)
04
Effectiveness of breastfeeding against pneumonia is estimated at ~4–13% reduction in pneumonia incidence (systematic review pooled estimate)
05
Improved household air quality (clean fuels/stoves) reduces pneumonia risk by ~20–30% (meta-analysis pooled estimate)
06
Exclusive breastfeeding for 6 months reduces pneumonia risk by ~25–50% (pooled evidence range in reviews)
07
Smoking cessation reduces risk of developing pneumonia by ~30% within years (population studies estimate)
Interpretation
Prevention & Vaccination Interpretation
For prevention and vaccination, the gap is clear that only 44% of infants globally receive the third dose of PCV by 2022, yet interventions like maternal influenza vaccination cutting infant lower respiratory infections by about 45% and maternal RSV vaccination reducing severe RSV disease by 68% show how much pneumonia burden could be averted.
report visual · Comparison
Pneumonia’s share of deaths in children under 5
Pneumonia accounts for a substantial portion of child mortality worldwide, including a large share driven by pneumonia and diarrhea together.
Deaths in low-income countries (children under 5) due to pneumonia26%
All childhood deaths due to pneumonia15%
Pneumonia + diarrhea attributable deaths (children under 5)14.9%
Leading infectious cause of death among children under 5 (many settings, approx.)5
1 in 7 deaths of children under 5 caused by pneumonia (approx.)1
source-verifiedourworldindata.org · unicef.org · who.int
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Pneumonia Statistics. Gitnux. https://gitnux.org/pneumonia-statistics
MLA
Lukas Bauer. "Pneumonia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pneumonia-statistics.
Chicago
Lukas Bauer. 2026. "Pneumonia Statistics." Gitnux. https://gitnux.org/pneumonia-statistics.
Sources & references
41 datasets cited across this report · attribution is report-level
+29 additional datasets cited (not shown individually)